Second, the measures of T2DM control and complications are limited, and data on the course of disease, the level of glucose control, C-peptide level, glycosylated haemoglobin, the treatment regimen and insulin use are lacking, which are important predictors of CVD risk for patients with T2DM [11]. This evidence concerns the gene INS and type 2 diabetes mellitus.